'This health emergency has brought a lot of people together with the common purpose of getting Feluda to play detective as quickly as possible.' 'As a scientist, if we can make a small difference in people's lives, we are happy'
'Antibodies remain in the blood for at least seven to nine months.'
'There is no emergency of a third wave that we are rushing for booster doses.'
The researchers noted that people who are fully vaccinated can still become infected with SARS-CoV-2 and can carry a viral load similar to those who are unvaccinated.
A 'very large' number of Indians are likely to remain protected from Omicron or any other variant of COVID-19 and there is no need to panic, eminent virologist Dr Shahid Jameel has said.
The ICMR has validated 'TruenatTM beta CoV test on TruelabTM workstation' and has recommended it as a screening test,the apex health research body said on Friday.
Coronaviruses, like other RNA viruses, can develop mutations in three different ways: by mistake from copying errors during viral replication, through interactions with other viruses infecting the same cell, or they can be induced by RNA modification systems which are part of host immunity, the researchers explained.
Serum Institute has the capacity to make 250 million doses of Covishield monthly.
A recent study by researchers at the Indian Institute of Technology (IIT) Gandhinagar has established the presence of coronavirus in water samples from the Sabarmati river and two lakes in Ahmedabad city of Gujarat.
'No matter how much the political pressure is, I cannot say I will bring the Moon for you tomorrow!'
Prime Minister Narendra Modi, in his address at the 76th session of the United Nations General Assembly on Saturday, invited the global manufacturers of vaccines to come and make vaccines in India, stressing that the country's "faith is to serve people".
Antibody levels are higher when people receive the COVID-19 vaccine in the afternoon as compared to the morning, according to an observational study.
Addressing a press briefing, Union Health Secretary Rajesh Bhushan said Zydus Cadila, Sputnik V, Biological E and Gennova are other vaccines also in the pipeline which are in advanced clinical trials in India.
The chronic inflammatory disease is affecting people globally.
The researchers from the the University of Texas Health Science Center at San Antonio (UT Health San Antonio) in the United States said by enabling this modification, nsp10 protects the virus from host cell immune response.
Scientists have identified antibodies that neutralise Omicron and other variants of coronavirus by targeting areas that remain essentially unchanged as the virus mutates.
The reason is that because of the hybrid immunity after three waves of natural infection and a large proportion of adults receiving both doses of COVID-19 vaccine, the susceptible pool has come down drastically, Lahariya said.
The vaccination rate needs to go up by three to four times, assert Ajay Shah and Amrita Agarwal.
An expert panel of the country's drugs regulatory authority had recommended against granting such approval to the firm at this stage just two days ago, officials said.
The Centre is conducting a study to assess the presence of SARS-CoV-2, or novel coronavirus, in the Ganga as corpses were found dumped in the river during the second Covid wave, and were fished out from districts in Uttar Pradesh and Bihar, officials said.
'Mortality or hospitalisation has not increased in South Africa because of the new variant.' 'There is nothing to show so far that it is more infectious.' 'I am of the opinion that at the moment, there is no reason to panic.'
This is the largest-ever purchase and donation of vaccines by a single country and a commitment by the American people to help protect people around the world from COVID-19, the White House said ahead of the announcement by Biden at the G-7 Summit in the UK.
The United Kingdom on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against COVID-19, paving the way for mass vaccinations against the deadly novel coronavirus.
Daily COVID-19 caseload in India that is currently around 7,500 infections is expected to increase once the Omicron starts displacing Delta as the dominant variant, informed members of the national COVID-19 supermodel committee and predicted the third wave in India early year.
India's drug regulator Drugs Controller General of India has granted permission to Mumbai-based pharmaceutical company Cipla to import Moderna's COVID-19 vaccine for restricted emergency use in the country, official sources said on Tuesday.
The reduced severity of the Omicron variant is good news for now, but it is the result of an 'evolutionary mistake' and does not indicate that the virus which causes COVID-19 is becoming less virulent, a leading Indian-origin scientist from the University of Cambridge warned on Thursday.
United States Pharma giant Pfizer is in the final stages of an agreement with India to supply anti-COVID-19 vaccines, Chief Executive Officer Dr Albert Bourla said on Tuesday, observing that the domestically manufactured vaccines would be the backbone of vaccinating the Indian people.
The amount of financial assistance to each state and Union Territories is based on their COVID-19 caseload.
In a letter to the state chief secretaries on Monday, ICMR Director General (D-G) Dr Balram Bhargava said the COVID-19 diagnostic supplies are stabilising because of the indigenous production of the kits.
Health Minister Harsh Vardhan said the COVID-19 vaccine will be available in the next few months and it is estimated that by July-August 400-500 million doses will be made available for 25-30 crore people.
Only half India's population has received the first shot of Covishield and Covaxin and the government's immediate task is to first vaccinate its adult population before placing its focus on children.
'What prevents infection are masks, physical distancing and good ventilation.'
'Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization for its COVID-19 vaccine in India'
The reduced severity of Omicron is good news for now, but it is the result of an "evolutionary mistake" as Covid-19 is transmitting very efficiently and there is no reason for it to become milder, indicating that the next variant could be more virulent, a leading Indian-origin scientist from the University of Cambridge has warned.
'The majority of transmission will be via people who are within two metres of one another.' 'The closer you are, the more likely that you'll be infected.'
Some vaccine frontrunners are in advanced stages of trial and could hit the market by early next year, making the task of securing "last mile connectivity" and ensuring that nothing goes wrong before the shot is administered more urgent.
'You will not have a vaccine for everyone initially.'
Scientists have used virus-like particles to predict how environmental factors affect the survival of the novel coronavirus on surfaces, and found that the COVID-19 virus may remain infectious longer as temperatures drop in winter.
The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
Calling vaccination an exercise in "preparedness and prevention", the vaccinologist said the immune response that is made has nothing to fight immediately but "we train the immune system to recognise the virus if and when it comes".
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances